Vertex Pharmaceuticals
VRTX
1,124 hedge funds and large institutions have $68.6B invested in Vertex Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 113 funds opening new positions, 433 increasing their positions, 408 reducing their positions, and 80 closing their positions.
41% more first-time investments, than exits
New positions opened: 113 | Existing positions closed: 80
25% more funds holding in top 10
Funds holding in top 10: 32 → 40 (+8)
2% more funds holding
Funds holding: 1,106 → 1,124 (+18)
1.08% more ownership
Funds ownership: 91.99% → 93.07% (+1.1%)
6% more repeat investments, than reductions
Existing positions increased: 433 | Existing positions reduced: 408
5% more capital invested
Capital invested by funds: $65.6B → $68.6B (+$3B)
2% more call options, than puts
Call options by funds: $445M | Put options by funds: $436M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$858M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$392M |
| 3 |
Amundi
Paris,
France
|
+$257M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$212M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$201M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$192M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$150M |
| 3 |
Holocene Advisors
New York
|
-$141M |
| 4 |
JP Morgan Chase
New York
|
-$109M |
| 5 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
-$103M |
VRTX Hedge Fund Activity: Q3 2022 in Review
1,124 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2022, worth a combined $68.6B — up 4.6% from $65.6B a quarter earlier.
Buyers outnumbered sellers: 113 funds opened new VRTX positions and 80 closed out — a net gain of 33 holders — while 433 added to existing stakes and 408 trimmed.
The largest buyer was Jennison Associates, adding an estimated $858M. The largest seller was First Trust Advisors, cutting an estimated $192M.
- 1,124 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2022, up from 1,106 in Q2 2022.
- Funds reported $68.6B of Vertex Pharmaceuticals stock for Q3 2022, up 4.6% quarter-over-quarter.
- 113 funds opened new Vertex Pharmaceuticals positions in Q3 2022 and 80 closed out, a net change of +33 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2022 was Jennison Associates, an estimated $858M added.
- The largest Vertex Pharmaceuticals seller in Q3 2022 was First Trust Advisors, an estimated $192M sold.
Based on aggregated 13F filings for Q3 2022.